Literature DB >> 21809353

Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2.

Tajana Tešan Tomić1, Heléne Gustavsson, Wanzhong Wang, Karin Jennbacken, Karin Welén, Jan-Erik Damber.   

Abstract

BACKGROUND: Angiogenesis is important for the progression of prostate cancer and may be a target for treatment in castration resistant (CR) disease. This study was performed to investigate blood vessel stabilization and expression of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and Angiopoietin-2 (Ang-2) in CR and hormone naïve (HN) prostate cancer. The effect of androgen deprivation therapy (ADT) on these parameters was also studied.
METHODS: VEGF and Ang-2, as well as pericyte coverage of blood vessels were studied in HN and CR prostate tumors by immunohistochemistry. The effects of ADT on VEGF expression and microvessel density (MVD) were investigated in biopsies at diagnosis, 3 months after starting ADT and at tumor relapse. Plasma was also analyzed for VEGF and Ang-2 with ELISA.
RESULTS: CR tumors had higher levels of VEGF and Ang-2 as well as increased blood vessel stabilization compared to HN tumors. Three months after initiated ADT an increase of VEGF but not MVD in the tumors was observed. In contrast, plasma levels of VEGF decreased after ADT, and increased again at time of tumor relapse. Ang-2 levels were unaffected.
CONCLUSIONS: CR prostate cancer is associated with elevated levels of VEGF and Ang-2, indicating that these factors could be used as targets for anti-angiogenic treatment. Still, the observed increase in blood vessel stabilization in CR tumors could influence the outcome of anti-angiogenic treatment. Furthermore, increased VEGF expression after 3 months of ADT justifies the use of VEGF-based anti-angiogenic drugs in combination with ADT for the treatment of advanced prostate cancer.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809353     DOI: 10.1002/pros.21472

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  21 in total

1.  P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.

Authors:  Hira Lal Goel; Bryan Pursell; Leonard D Shultz; Dale L Greiner; Rolf A Brekken; Craig W Vander Kooi; Arthur M Mercurio
Journal:  Cell Rep       Date:  2016-02-25       Impact factor: 9.423

Review 2.  Gene variants in the angiogenesis pathway and prostate cancer.

Authors:  Ernest K Amankwah; Thomas A Sellers; Jong Y Park
Journal:  Carcinogenesis       Date:  2012-04-20       Impact factor: 4.944

3.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.

Authors:  Vasundhra Kashyap; Shafqat Ahmad; Emeli M Nilsson; Leszek Helczynski; Sinéad Kenna; Jenny Liao Persson; Lorraine J Gudas; Nigel P Mongan
Journal:  Mol Oncol       Date:  2013-01-19       Impact factor: 6.603

4.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

5.  Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.

Authors:  Tae-Dong Kim; Fang Jin; Sook Shin; Sangphil Oh; Stan A Lightfoot; Joseph P Grande; Aaron J Johnson; Jan M van Deursen; Jonathan D Wren; Ralf Janknecht
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

6.  Methylselenocysteine preventing castration-resistant progression of prostate cancer.

Authors:  Yanbo Liu; Xichun Liu; Yaxiong Guo; Zuowen Liang; Yong Tian; Lili Lu; Xiaohui Zhao; Ying Sun; Xuejian Zhao; Haitao Zhang; Yan Dong
Journal:  Prostate       Date:  2015-03-08       Impact factor: 4.104

7.  RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.

Authors:  Monica Logan; Philip D Anderson; Shahrazad T Saab; Omar Hameed; Sarki A Abdulkadir
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

8.  Emerging targeted therapies for castration-resistant prostate cancer.

Authors:  Vincenzo Adamo; Laura Noto; Tindara Franchina; Giuseppe Chiofalo; Maria Picciotto; Giuseppe Toscano; Nicola Caristi
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-31       Impact factor: 5.555

9.  Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610.

Authors:  Larry Pan; Seunghee Baek; Pamela R Edmonds; Mack Roach; Harvey Wolkov; Satish Shah; Alan Pollack; M Elizabeth Hammond; Adam P Dicker
Journal:  Radiat Oncol       Date:  2013-04-25       Impact factor: 3.481

10.  Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.

Authors:  R Joseph Bender; Feilim Mac Gabhann
Journal:  BMC Syst Biol       Date:  2015-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.